TOBRADEX

Phase 3Small molecule

AAlcon Research

TOBRADEX is one of 32 small molecule programs targeting Bacterial Conjunctivitis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Bacterial ConjunctivitisActive, not recruiting

BlepharitisActive, not recruiting

Bacterial ConjunctivitisPhase 3

Active, not recruiting

BlepharitisPhase 3

Active, not recruiting

Competition

Competitive Landscape

39 competitors in Blepharitis

#DrugCompanyPhaseTrials

E-Mycin

AAzurity Pharmaceuticals

Approved

1 2

Stromectol

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Levaquin

Elidel

BBausch Health Americas, Inc.

Approved

—5

Tobrex

VViatris Specialty LLC

Flagyl

Lotemax

1 8

Decadron

AAspen Global Incorporated

Phase 3

1 9

Flovent

GSK

Phase 2

1 10

Azasite

Merck & Co.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Dexamethasone1 trial

TOBRADEX Ophthalmic Suspension Versus Tobramycin 0.3%/Dexamethasone 0.05% Ophthalmic Suspension

Completed·AAlcon Research·Phase 3·NCT00576251·221 enrolled

Bacterial Conjunctivitis1 trial

Effectiveness Comparison Between the Drugs TOBRACORT® and TOBRADEX® in Reducing the Signs and Symptoms of Acute Bacterial Conjunctivitis

Unknown status·AAzidus Brasil·Phase 3·NCT01227915·70 enrolled

Blepharitis1 trial

A Study to Evaluate the Clinical Efficacy and Safety of Tobradex® ST Compared to Azasite® in the Treatment of Subjects With Moderate to Severe Chronic Blepharitis

Completed·AAlcon Research·Phase 3·NCT01102244·122 enrolled

CLE1 trial

Tobradex BID Compared to TOBRADEX and TOBREX/Vehicle

Withdrawn·AAlcon Research·Phase 3·NCT00404937

Concentration1 trial

Tobramycin Tear Concentrations

Completed·AAlcon Research·Phase 1·NCT00695435·21 enrolled

1 more indication

Unspecified1 trial

A Clinical Study of Tobradex AF

Completed·AAlcon Research·Phase 3·NCT00473070·900 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for TOBRADEX. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TOBRADEX compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TOBRADEX. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Alcon Research company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AAlcon Research

TOBRADEX

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Dexamethasone1 trial

Bacterial Conjunctivitis1 trial

Blepharitis1 trial

CLE1 trial

Concentration1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News